Ettinger B
J Clin Pharmacol. 1985 Jul-Aug;25(5):365-8. doi: 10.1002/j.1552-4604.1985.tb02856.x.
As triamterene users may form kidney stones containing deposits of triamterene and its metabolites, we studied urinary excretion to detect any altered metabolism of triamterene in these patients. We found no significant differences between patients and matched control subjects in total recovery, hourly excretion patterns, and concentrations of triamterene and its sulfate metabolite. Approximately half of all subjects tested revealed urine concentrations of the sulfate metabolite that exceeded the observed solubility limit.
由于氨苯蝶啶使用者可能会形成含有氨苯蝶啶及其代谢产物沉积物的肾结石，我们研究了尿液排泄情况，以检测这些患者中氨苯蝶啶的代谢是否有任何改变。我们发现，患者与匹配的对照受试者在总回收率、每小时排泄模式以及氨苯蝶啶及其硫酸盐代谢产物的浓度方面没有显著差异。在所有接受测试的受试者中，约有一半的人尿液中硫酸盐代谢产物的浓度超过了观察到的溶解度极限。
